Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Cash Position
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(178)
•••
Comment by Layth1990on Oct 18, 2021 6:31pm
334 Views
Post# 34020244

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Cash Position

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Cash Position

Hard work? What are you taking about ? This guy fu*ked everyone and he sold some because he knew about atb 346 issues and it is against the law to do that as an insider. Stop giving excuses, this guy must leave and the company will rise after that because anyone will outperform his sh*tty performance.  


he doesn't know what he is doing. I can't get out of mind his reverse split plan and nasdaq uplisting, selling before bad news and buying some after to make it look deligent lol. He is full of doubt and all his news releases are full with words like (upcomming, potentially, ..) not even once he met the deadlines and always delays. What is good about Dan ? Give me one reason only

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities